Page last updated: 2024-12-06

opc 14117

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

OPC 14117: has both brain function activating effect & protective effect against cerebral ischemia; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID59739
CHEMBL ID56373
SCHEMBL ID195726
MeSH IDM0201920

Synonyms (15)

Synonym
opc-14117
opc 14117
bdbm50084314
n-(7-hydroxy-2,2,4,6-tetramethyl-indan-1-yl)-2-[4-(3-methoxy-phenyl)-piperazin-1-yl]-acetamide
CHEMBL56373 ,
n-(7-hydroxy-2,2,4,6-tetramethyl-1,3-dihydroinden-1-yl)-2-[4-(3-methoxyphenyl)piperazin-1-yl]acetamide
1-piperazineacetamide, n-(2,3-dihydro-7-hydroxy-2,2,4,6-tetramethyl-1h-inden-1-yl)-4-(3-methoxyphenyl)-
7-hydroxy-1-(4-(3-methoxyphenyl)-1-piperazinyl)acetylamino-2,2,4,6-tetramethylindan
103233-65-4
4zh798u6iq ,
unii-4zh798u6iq
SCHEMBL195726
Q27260716
DTXSID70908266
n-(7-hydroxy-2,2,4,6-tetramethyl-2,3-dihydro-1h-inden-1-yl)-2-[4-(3-methoxyphenyl)piperazin-1-yl]ethanimidic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We hypothesized that OPC-14117, a lipophilic antioxidant that acts to scavenge superoxide anion radicals, might ameliorate the toxic interactions between HIV infected macrophages and neurons."( Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.
, 1997
)
0.3
" There were no significant differences between treatment arms in the primary measures of tolerability, the frequency and types of clinical adverse events, or the clinical/functional features of HD."( Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group.
, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
" The primary outcome was tolerability of the study drug as measured by the proportion of subjects able to complete the study on their assigned dosage of experimental medication."( Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.
, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)15.00000.00030.55704.2000AID204605
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID204605Binding affinity for sigma receptor was evaluated by the inhibitory effect on [3H]DTG to rat whole brain membranes2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID119416Compound was tested for the anesthetic effect and the sleeping time (ST) was recorded at a dose of 10 mg/kg administered orally.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID119429Antihypoxic effect tested by the ratio of survival time (SVT) of test mice to that of control group, dosed intraperitoneally at 30 mg/kg1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID119564Antihypoxic effect by the survival time (SVT) in mice at a dose of 3 mg/kg administered intraperitoneally.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID222712Effect on recovery time for coma induced in mice by cerebral concussion (treated group)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID119405Spontaneous movement (SMT) in seconds, was measured after oral administration of 30 mg/kg in mice to test for promoting effects on recovery from coma.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID119430Antihypoxic effect tested by the ratio of survival time (SVT) of test mice to that of control group, dosed orally 30 mg/kg1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID119256Time of recovery of spontaneous movement (SMT) in seconds was measured after administration of 0.3 mg/kg orally in mice for the promotional effect on recovery from coma.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID222714Effect on the time required for recovery from coma induced in mice by cerebral concussion at the dose of 30 mg/kg po2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID119400Time of recovery of spontaneous movement (SMT) in seconds was measured after administration of 1 mg/kg orally in mice for the promotional effect on recovery from coma.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID119418Compound was tested for the anesthetic effect and the sleeping time (ST) was recorded at a dose of 1 mg/kg administered orally.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID119189Time of recovery of righting reflux (RRT) in seconds was measured after administration of 3 mg/kg orally in mice for the promotional effect on recovery from coma.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID225163Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 1 mg/kg po2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID222713Effect on the time required for recovery from coma induced in mice by cerebral concussion at the dose of 10 mg/kg po2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID119188Time of recovery of righting reflux (RRT) in seconds was measured after oral administration of 30 mg/kg in mice for the promotional effect on recovery from coma.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID119183Time of recovery of righting reflux (RRT) in seconds was measured after administration of 1 mg/kg orally in mice for the promotional effect on recovery from coma.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID225160Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 10 mg/kg po2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID119064Time of recovery of righting reflux (RRT) in seconds was measured after administration of 0.3 mg/kg orally in mice for the promotional effect on recovery from coma.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID225042Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 0 mg/kg po2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID119421Compound was tested for the anesthetic effect and the sleeping time (ST) was recorded at a dose of 3 mg/kg administered orally.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID222711Effect on recovery time for coma induced in mice by cerebral concussion (control group)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID223173Effect on the sleeping time of mice anesthetized with halothane (treated group)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID119406Time of recovery of spontaneous movement (SMT) in seconds was measured after administration of 3 mg/kg orally in mice for the promotional effect on recovery from coma.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID119426Antihypoxic effect by the ratio of survival time (SVT) of test mice to that of control group at a dose of 10 mg/kg administered intraperitoneally.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives.
AID223176Effect on the sleeping time of mice before halothane load (control group)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (75.00)18.2507
2000's4 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.16 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (18.75%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia [NCT00002148]Phase 130 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]